Drug Profile
Itriglumide
Alternative Names: CR-2945Latest Information Update: 11 Apr 2016
Price :
$50
*
At a glance
- Originator Rottapharm
- Developer Rottapharm Madaus
- Class Antiulcers; Anxiolytics
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Gastrointestinal cancer; Gastrointestinal disorders
- Discontinued Sleep apnoea syndrome
Most Recent Events
- 11 Apr 2016 Rottapharm completes a phase II trial for Sleep apnoea syndrome in Italy (EudraCT2013-004469-15) prior to April 2016
- 15 Oct 2015 Discontinued - Phase-II for Sleep apnoea syndrome (Treatment-naive) in Italy (PO)
- 17 Aug 2015 No recent reports on development identified - Phase-II for Anxiety disorders, Gastrointestinal cancer, and Gastrointestinal disorders in Italy (unspecified route)